www.immunotarget.bio

About www.immunotarget.bio

ImmunoTarget Therapeutics develops personalized immunotherapies using its proprietary ImmuniT™ Platform, which processes tumor and blood samples to enrich for tumor neoantigens and prime the patient's immune cells. This approach addresses the challenge of tumor heterogeneity by creating a unique vaccine that trains the immune system to recognize and eliminate diverse cancer cells while sparing healthy tissue.

```xml <problem> Current cancer immunotherapies often fall short due to tumor heterogeneity, where diverse cancer cells within a patient's tumor possess unique genetic variances. Existing treatments, which rely on population-level genetics to engineer immune cells, struggle to comprehensively recognize and eliminate this multitude of personalized cancer cells, potentially leading to incomplete tumor eradication and recurrence. </problem> <solution> ImmunoTarget Therapeutics addresses this limitation with a patient-specific, biologically derived immunotherapy created through its ImmuniT™ Platform. The platform processes tumor and blood samples to enrich for tumor neoantigens, which are then used to prime the patient's own immune cells. This process creates a unique vaccine that trains the immune system to recognize and destroy each type of cancer cell within the tumor while sparing healthy cells. This customized approach aims to increase the probability of complete tumor elimination and decrease the chance of cancer recurrence. </solution> <features> - ImmuniT™ Platform for processing patient tumor and blood samples - Enrichment of tumor neoantigens to create personalized vaccines - Training of patient's immune cells to target diverse cancer cells - Biologically derived immunotherapy, avoiding genetic engineering of immune cells - Designed to recognize and destroy all types of cancer cells within a tumor </features> <target_audience> The primary target audience includes oncology researchers and clinicians focused on developing personalized cancer treatments, as well as patients seeking innovative immunotherapy options. </target_audience> ```

What does www.immunotarget.bio do?

ImmunoTarget Therapeutics develops personalized immunotherapies using its proprietary ImmuniT™ Platform, which processes tumor and blood samples to enrich for tumor neoantigens and prime the patient's immune cells. This approach addresses the challenge of tumor heterogeneity by creating a unique vaccine that trains the immune system to recognize and eliminate diverse cancer cells while sparing healthy tissue.

0

Find Investable Startups and Competitors

Search thousands of startups using natural language

www.immunotarget.bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ImmunoTarget Therapeutics develops personalized immunotherapies using its proprietary ImmuniT™ Platform, which processes tumor and blood samples to enrich for tumor neoantigens and prime the patient's immune cells. This approach addresses the challenge of tumor heterogeneity by creating a unique vaccine that trains the immune system to recognize and eliminate diverse cancer cells while sparing healthy tissue.

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Current cancer immunotherapies often fall short due to tumor heterogeneity, where diverse cancer cells within a patient's tumor possess unique genetic variances. Existing treatments, which rely on population-level genetics to engineer immune cells, struggle to comprehensively recognize and eliminate this multitude of personalized cancer cells, potentially leading to incomplete tumor eradication and recurrence.

Solution

ImmunoTarget Therapeutics addresses this limitation with a patient-specific, biologically derived immunotherapy created through its ImmuniT™ Platform. The platform processes tumor and blood samples to enrich for tumor neoantigens, which are then used to prime the patient's own immune cells. This process creates a unique vaccine that trains the immune system to recognize and destroy each type of cancer cell within the tumor while sparing healthy cells. This customized approach aims to increase the probability of complete tumor elimination and decrease the chance of cancer recurrence.

Features

ImmuniT™ Platform for processing patient tumor and blood samples

Enrichment of tumor neoantigens to create personalized vaccines

Training of patient's immune cells to target diverse cancer cells

Biologically derived immunotherapy, avoiding genetic engineering of immune cells

Designed to recognize and destroy all types of cancer cells within a tumor

Target Audience

The primary target audience includes oncology researchers and clinicians focused on developing personalized cancer treatments, as well as patients seeking innovative immunotherapy options.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.